Clinical trialPhase 2Completed
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- January 2009
- Expected end
- July 2012
- Enrollment
- 41 participants
- Sites
- 3
- Primary outcomes
- Survival Rate
- Sponsor
- Industry
- Results posted
- No
- Last update
- 6 September 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try